AU Patent

AU2016220235A1 — Nasal powder formulation for treatment of hypoglycemia

Assigned to Amphastar Pharmaceuticals Inc · Expires 2017-07-20 · 9y expired

What this patent protects

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powd…

USPTO Abstract

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016220235A1
Jurisdiction
AU
Classification
—
Expires
2017-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Amphastar Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.